62 completed. 62 Phase 2, 17 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 62 | Completed 62 |
| Phase 1 | 17 | Completed 17 |
| Phase 3 | 4 | Completed 4 |
Follow Skin Abnormalities: new trials by email Literature Review of Skin Abnormalities trials Research Report on Skin Abnormalities
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparison of Rimegepant and Placebo for Pain in IBS Rimegepant 75 MG [Nurtec] - Irritable Bowel Syndrome | Phase 2 | Completed | Mayo Clinic | 39 | 2024-06-06 | 2026-10-15 |
| A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory Genodermatoses deucravacitinib - Epidermolysis Bullosa Simplex, Ichthyosis | Phase 2 | Completed | Centre Hospitalier Universitaire de Nice | 8 | 2024-03-18 | 2026-10-16 |
| ADX-629 Therapy for Sjogren-Larsson Syndrome ADX-629 - Sjogren-Larsson Syndrome | Phase 1 / Phase 2 | Completed | University of Nebraska | 8 | 2023-01-02 | 2026-05-05 |
| A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum DS-1211b, Placebo - Pseudoxanthoma Elasticum | Phase 2 | Completed | Daiichi Sankyo | 65 | 2022-10-20 | 2024-12-31 |
| Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ABCC6 Deficiency Causing PXE INZ-701 - ATP-Binding Cassette Subfamily C Member 6 Deficiency, Pseudoxanthoma Elasticum | Phase 1 / Phase 2 | Completed | Inozyme Pharma | 10 | 2022-04-11 | 2026-10-13 |
| INM-755 (Cannabinol) Cream for Treatment of Epidermolysis Bullosa INM-755 (cannabinol) cream, Vehicle Cream - Epidermolysis Bullosa Simplex, Epidermolysis Bullosa, Junctional | Phase 2 | Completed | InMed Pharmaceuticals Inc. | 19 | 2021-12-28 | 2023-07-03 |
| A Study to Evaluate Topically Applied SXR1096 Cream in Patients With Netherton Syndrome SXR1096 cream, Placebo cream - Netherton Syndrome | Phase 1 / Phase 2 | Completed | Sixera Pharma | 9 | 2021-12-07 | 2025-12-16 |
| Extension Study to PTR-01-002 (A Study in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Patients Previously Treated With PTR-01) PTR-01 - Recessive Dystrophic Epidermolysis Bullosa | Phase 2 | Completed | Phoenix Tissue Repair, Inc. | 2 | 2021-12-02 | 2022-11-21 |
| Rigosertib for RDEB-SCC Rigosertib Oral Capsules / Rigosertib Intravenous - Epidermolysis Bullosa Dystrophica, Squamous Cell Carcinoma | Phase 1 / Phase 2 | Completed | Prof. Johann Bauer | 2 | 2021-04-12 | 2026-02-24 |
| Topical Gentamicin Nonsense Suppression Therapy of EB Gentamicin Sulfate - Epidermolysis Bullosa | Phase 1 / Phase 2 | Completed | Oslo University Hospital | 4 | 2020-12-01 | 2022-05-03 |
| A Study of PTR-01 in Recessive Dystrophic Epidermolysis Bullosa PTR-01 - Recessive Dystrophic Epidermolysis Bullosa | Phase 2 | Completed | Phoenix Tissue Repair, Inc. | 6 | 2020-10-15 | 2021-09-16 |
| A Vehicle Controlled Study to Evaluate Safety and Efficacy of Topical TMB-001 for Treatment of Congenital Ichthyosis Isotretinoin, Vehicle - Congenital Ichthyosis | Phase 2 | Completed | LEO Pharma | 34 | 2019-12-03 | 2026-05-22 |
| A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa Serlopitant Tablet, Placebo Oral Tablet - Epidermolysis Bullosa | Phase 2 | Completed | Stanford University | 28 | 2019-04-18 | 2023-02-14 |
| Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita PTX-022, Placebo - Pachyonychia Congenita | Phase 2 / Phase 3 | Completed | Palvella Therapeutics, Inc. | 73 | 2019-04-01 | 2024-08-29 |
| Allogeneic ABCB5-positive Stem Cells for Treatment of Epidermolysis Bullosa allo-APZ2-EB - Recessive Dystrophic Epidermolysis Bullosa | Phase 1 / Phase 2 | Completed | RHEACELL GmbH & Co. KG | 16 | 2019-02-16 | 2022-10-07 |
| A Phase 1/2 Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB) PTR-01, Normal saline - Recessive Dystrophic Epidermolysis Bullosa | Phase 1 / Phase 2 | Completed | Phoenix Tissue Repair, Inc. | 12 | 2019-01-09 | 2021-03-09 |
| Injections of Botulinic Toxin in Plantar Lesions of Localized Epidermolysis Bullosa Simplex Botulinic toxin, Placebo - Epidermolysis Bullosa Simplex | Phase 2 / Phase 3 | Completed | University Hospital, Toulouse | 18 | 2018-06-14 | 2026-09-21 |
| A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients Topical beremagene geperpavec, Placebo gel - Dystrophic Epidermolysis Bullosa | Phase 1 / Phase 2 | Completed | Krystal Biotech, Inc. | 12 | 2018-05-06 | 2023-01-31 |
| Long Term Open-label Study Evaluating Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex diacerein 1% ointment - Epidermolysis Bullosa, Epidermolysis Bullosa Simplex | Phase 2 | Completed | Castle Creek Pharmaceuticals, LLC | 51 | 2017-12-01 | 2020-09-16 |
| A Six Week Topical Cream Study for Subjects With Ichthyosis Vulgaris 146-9251 cream, Vehicle cream - Ichthyosis Vulgaris | Phase 2 | Completed | Crown Laboratories, Inc. | 80 | 2017-04-25 | 2021-08-10 |
Showing 20 of 62. Sign in to see all of them.
Epidermolysis Bullosa (16) · Epidermolysis Bullosa Dystrophica (14) · Pseudoxanthoma Elasticum (6) · Epidermolysis Bullosa Simplex (5) · Ichthyosis (4) · Ichthyosis Bullosa of Siemens (4) · Netherton Syndrome (4) · Dyskeratosis Congenita (3) · Ichthyosis Vulgaris (3) · Irritable Bowel Syndrome (3) · Anemia, Aplastic (2) · Angioid Streaks (2) · Choroidal Neovascularization (2) · Constipation (2)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (62) · Skin and Connective Tissue Diseases (61) · Congenital Abnormalities (60) · Skin Diseases (59) · Genetic Diseases, Inborn (56) · Skin Diseases, Genetic (54) · Skin Diseases, Vesiculobullous (29) · Connective Tissue Diseases (22) · Keratosis (16) · Collagen Diseases (15) · Epidermolysis Bullosa (13) · Infant, Newborn, Diseases (13) · Pathological Conditions, Signs and Symptoms (13) · Ichthyosis (12)
Antilymphocyte Serum (4) · Whole-Body Irradiation (4) · fludarabine phosphate (4) · Cyclophosphamide (3) · Gentamicins (3) · fludarabine (3) · thymoglobulin (3) · Mycophenolic Acid (2) · Ranibizumab (2) · Stem Cell Transplantation (2) · Tacrolimus (2) · serlopitant (2) · 3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol (1) · ADX-629 (1) · Adalimumab (1)
Centre Hospitalier Universitaire de Nice (3) · Masonic Cancer Center, University of Minnesota (3) · Mayo Clinic (3) · Phoenix Tissue Repair, Inc. (3) · National Center for Research Resources (NCRR) (2) · Northwestern University (2) · Stanford University (2) · University Hospital, Bonn (2) · University of Southern California (2) · Abeona Therapeutics, Inc (1) · Aldeyra Therapeutics, Inc. (1) · Anterogen Co., Ltd. (1) · Assistance Publique - Hôpitaux de Paris (1) · Bayer (1) · Birken AG (1)
United States (40) · France (11) · Germany (8) · Italy (4) · Austria (3) · Canada (3) · United Kingdom (3) · Netherlands (2) · Norway (2) · South Korea (2) · Sweden (2) · Australia (1) · Belgium (1) · Dominican Republic (1) · Greece (1)
Jakub Tolar, MD, PhD (3) · David Woodley, MD (2) · Jean Tang, MD, PhD (2) · Agnes Schwieger-Briel, MD (1) · Albert C Yan, MD (1) · Albert S Chiou, MD/MBA (1) · Alexandra DJ Mancini, MSc (1) · Amy Paller, MD (1) · Amy S Paller, MD (1) · Brian Berman, M.D., Ph.D. (1) · Christine Bodemer, MD, PhD (1) · Christine Chiaverini (1) · Christine Chiaverini, PhD (1)
PMID 31541747, PMID 20083693, PMID 20383216, PMID 20691689, PMID 21704964, PMID 22517769, PMID 24102348, PMID 24952730, PMID 27015660, PMID 27802546, PMID 28691931, PMID 30843184, PMID 31578311, PMID 33011075, PMID 33214244, PMID 33491668, PMID 34665781, PMID 35218370, PMID 35347281, PMID 36253825, PMID 36868990, PMID 37170057, PMID 41637861
UL1RR024150 (2), 1RC1DK086182 (1), 2017 (1), P30CA015704 (1), R01AR055914 (1), R01DK054681 (1), R01DK079866 (1)